Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression

Annals of Hematology

Volumn 89, Issue 4, 2010, Pages 365-374

  Göhring, Gudrun ^a   Giagounidis, Aristoteles ^b   Büsche, Guntram ^a   Kreipe, Hans Heinrich ^a   Zimmermann, Martin ^a   Hellstr̈m Lindberg, Eva ^c   Aul, Carlo ^b   Schlegelberger, Brigitte ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b ST JOHANNES HOSPITAL   (Germany)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

5q deletion; Acute myeloid leukaemia; Clonal evolution; Complex karyotype; Lenalidomide; Leukaemia transformation; Myelodysplastic syndrome

Indexed keywords

LENALIDOMIDE; DRUG DERIVATIVE; THALIDOMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER INCIDENCE; CHROMOSOME 5Q; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CLINICAL ARTICLE; CLONE; CONTROLLED STUDY; CYTOGENETICS; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKEMOGENESIS; MALE; MALIGNANT TRANSFORMATION; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; CHROMOSOME 5; DRUG EFFECT; ERYTHROID CELL; GENETICS; KARYOTYPING; MIDDLE AGED; PATHOLOGY; REMISSION; RISK FACTOR; TREATMENT FAILURE;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; DISEASE PROGRESSION; ERYTHROID CELLS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; REMISSION INDUCTION; RISK FACTORS; THALIDOMIDE; TREATMENT FAILURE;

EID: 77649303359     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-009-0846-z     Document Type: Article

References (28)

1. Jaffe ES, Harris NL, Stein H, Vardiman JW (2001) World health organization classification of tumours vol. 3. Pathology and genetics: tumours of haematopoietic and lymphoid tissues. IARC, Lyon
2. Cazzola M, Malcovati L (2005) Myelodysplastic syndromes- coping with ineffective hematopoiesis. N Engl J Med 352(6):536-538
3. Van den Berghe H, Vermaelen K, Mecucci C, Barbieri D, Tricot G (1985) The 5q- anomaly. Cancer Genet Cytogenet 17(3):189-255
4. Boultwood J, Lewis S, Wainscoat JS (1994) The 5q- syndrome. Blood 84(10):3253-3260
5. Tasaka T, Tohyama K, Kishimoto M, Ohyashiki K, Mitani K, Hotta T et al (2008) Myelodysplastic syndrome with chromosome 5 abnormalities: a nationwide survey in Japan. Leukemia 22 (10):1874-1881
6. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R et al (2007) Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25(23):3503-3510
7. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E et al (2006) Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355(14):1456-1465
8. List AF (2005) Emerging data on IMiDs in the treatment of yelodysplastic syndromes (MDS). Semin Oncol 32(4 Suppl 5): S31-S35
9. Giagounidis A, Fenaux P, Mufti GJ, Muus P, Platzbecker U, Sanz G, Cripe L, Lilienfeld-Toal M, Wells RA (2008) Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes. Ann Hematol 87(5):345-352
10. Giagounidis AA, Haase S, Heinsch M, Gohring G, Schlegelberger B, Aul C (2007) Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses. Ann Hematol 86(2):133-137
11. Schlegelberger B, Metzke S, Harder S, Zühlke-Jenisch R, Zhang Y, Siebert R (1999) Classical and molecular cytogenetics of tumor cells. In: Wegener R (ed) Diagnostic cytogenetics. Springer, Heidelberg, pp 151-185
12. ISCN (1995) Guidelines for cancer cytogenetics, supplement to an international system for human cytogenetic nomenclature. Mitelman F (ed) S Karger, Basel
13. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51(2):189-199
14. Jaffe ES, Harris NL, Diebold J, Muller-Hermelink HK (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. A progress report. Am J Clin Pathol 111(1 Suppl 1):S8-S12
15. Cox DR (1972) Regression models and life tables. J R Stat Soc 34:187
16. Gray RJ (1988) A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154
17. Kalbfleisch JD, Prentice RL (1980) The statistical analysis of failure time data (ed 1). Wiley, New York
18. Farag SS, Archer KJ, Mrozek K, Ruppert AS, Carroll AJ, Vardiman JW et al (2006) Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood 108(1):63-73
19. Haase D, Germing U, Schanz J, Pfeilstocker M, Nosslinger T, Hildebrandt B et al (2007) New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 110 (13):4385-4395
20. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89(6):2079-2088
21. Giagounidis AA, Germing U, Haase S, Hildebrandt B, Schlegelberger B, Schoch C et al (2004) Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia 18(1):113-119
22. List A (2008) Immunomodulatory drugs in myelodysplastic syndromes: long-term outcome. Hematol Educ 2(1):91-94
23. List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D et al (2005) Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352(6):549-557
24. Mallo M, Arenillas L, Espinet B, Salido M, Hernandez JM, Lumbreras E et al (2008) Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-. Haematologica 93(7):1001-1008
25. Jädersten MS, Saft L, Pellagatti P, Göhring G, Nilsson L, Wainscoat JS, Boultwood J, Porwit A, Schlegelberger B, Hellström-Lindberg E (2009) Clonal heterogeneity in the 5qsyndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression. Haematologica (in press)
26. Göhring G, Schlegelberger B, Hellström-Lindberg E (2008) Myelodysplastic syndromes. In: Stilgenbauer S, Döhner H (eds) Molecular diagnostics in hematological oncology. UNI-MED, Bremen, pp 117-125
27. Ebert BL, Pretz J, Bosco J, Chang CY, Tamayo P, Galili N et al (2008) Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 451(7176):335-339
28. Galili N, Raza A (2006) Immunomodulatory drugs in myelodysplastic syndromes. Expert Opin Investig Drugs 15(7):805-813